Toppgene analysis for Wikipedia protein communities, toppgene analysis, cc125_19, positive side

Go To Start Page
Input Parameters [Show Detail]
Training Results [Expand All] [Download All] [Sparse Matrix]
Display pValues and Scores as Table row limit

1: GO: Molecular Function [Display Chart] 19 input genes in category / 56 annotations before applied cutoff / 18661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0004709 MAP kinase kinase kinase activity 1.167E-30 6.538E-29 3.015E-28 6.538E-29 12 30
2 GO:0004674 protein serine/threonine kinase activity 1.634E-21 4.576E-20 2.110E-19 9.152E-20 15 452
3 GO:0031434 mitogen-activated protein kinase kinase binding 2.946E-9 5.499E-8 2.536E-7 1.650E-7 4 19
4 GO:0004706 JUN kinase kinase kinase activity 1.469E-7 2.056E-6 9.483E-6 8.226E-6 3 11
5 GO:0004713 protein tyrosine kinase activity 3.026E-5 3.389E-4 1.563E-3 1.694E-3 4 182
6 GO:0004708 MAP kinase kinase activity 1.846E-4 1.631E-3 7.522E-3 1.034E-2 2 20
7 GO:0043539 protein serine/threonine kinase activator activity 2.039E-4 1.631E-3 7.522E-3 1.142E-2 2 21
8 GO:0031435 mitogen-activated protein kinase kinase kinase binding 2.453E-4 1.717E-3 7.920E-3 1.374E-2 2 23
9 GO:0004712 protein serine/threonine/tyrosine kinase activity 1.077E-3 6.314E-3 2.912E-2
6.033E-2
 2 48
10 GO:0000287 magnesium ion binding 1.128E-3 6.314E-3 2.912E-2
6.314E-2
 3 206
11 GO:0097110 scaffold protein binding 1.412E-3 7.190E-3 3.316E-2
7.909E-2
 2 55
12 GO:0030295 protein kinase activator activity 2.816E-3 1.274E-2
5.873E-2
1.577E-1
 2 78
13 GO:0019002 GMP binding 3.052E-3 1.274E-2
5.873E-2
1.709E-1
 1 3
14 GO:0031267 small GTPase binding 3.324E-3 1.274E-2
5.873E-2
1.862E-1
 3 301
15 GO:0019209 kinase activator activity 3.411E-3 1.274E-2
5.873E-2
1.910E-1
 2 86
16 GO:0051020 GTPase binding 4.195E-3 1.468E-2
6.771E-2
2.349E-1
 3 327
17 GO:0008432 JUN kinase binding 1.316E-2 4.335E-2
1.999E-1
7.369E-1
 1 13
18 GO:0046625 sphingolipid binding 1.617E-2 4.872E-2
2.247E-1
9.057E-1
 1 16
19 GO:0019887 protein kinase regulator activity 1.653E-2 4.872E-2
2.247E-1
9.256E-1
 2 195
Show 14 more annotations

2: GO: Biological Process [Display Chart] 19 input genes in category / 727 annotations before applied cutoff / 18623 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0000186 activation of MAPKK activity 1.265E-29 9.196E-27 6.591E-26 9.196E-27 13 57
2 GO:0043405 regulation of MAP kinase activity 2.091E-25 7.601E-23 5.447E-22 1.520E-22 16 356
3 GO:0032147 activation of protein kinase activity 7.283E-24 1.765E-21 1.265E-20 5.294E-21 15 316
4 GO:0045860 positive regulation of protein kinase activity 4.548E-23 8.266E-21 5.924E-20 3.306E-20 16 496
5 GO:0051403 stress-activated MAPK cascade 1.566E-22 2.277E-20 1.632E-19 1.139E-19 14 272
6 GO:0031098 stress-activated protein kinase signaling cascade 2.138E-22 2.591E-20 1.857E-19 1.555E-19 14 278
7 GO:0032872 regulation of stress-activated MAPK cascade 3.745E-17 3.578E-15 2.564E-14 2.722E-14 11 222
8 GO:0070302 regulation of stress-activated protein kinase signaling cascade 3.937E-17 3.578E-15 2.564E-14 2.862E-14 11 223
9 GO:0007254 JNK cascade 3.015E-15 2.436E-13 1.746E-12 2.192E-12 10 216
10 GO:0043406 positive regulation of MAP kinase activity 6.208E-15 4.514E-13 3.235E-12 4.514E-12 10 232
11 GO:0032874 positive regulation of stress-activated MAPK cascade 1.229E-14 7.903E-13 5.664E-12 8.937E-12 9 154
12 GO:0070304 positive regulation of stress-activated protein kinase signaling cascade 1.304E-14 7.903E-13 5.664E-12 9.483E-12 9 155
13 GO:0071902 positive regulation of protein serine/threonine kinase activity 1.621E-13 9.067E-12 6.498E-11 1.179E-10 10 321
14 GO:0046330 positive regulation of JNK cascade 3.870E-13 2.010E-11 1.440E-10 2.813E-10 8 133
15 GO:0043507 positive regulation of JUN kinase activity 8.306E-13 4.026E-11 2.885E-10 6.039E-10 7 78
16 GO:0000187 activation of MAPK activity 1.490E-12 6.768E-11 4.851E-10 1.083E-9 8 157
17 GO:0043506 regulation of JUN kinase activity 4.970E-12 2.075E-10 1.487E-9 3.614E-9 7 100
18 GO:0046328 regulation of JNK cascade 5.138E-12 2.075E-10 1.487E-9 3.736E-9 8 183
19 GO:0007257 activation of JUN kinase activity 8.327E-10 3.186E-8 2.283E-7 6.053E-7 5 46
20 GO:0046777 protein autophosphorylation 1.146E-7 4.167E-6 2.987E-5 8.334E-5 6 245
21 GO:1900745 positive regulation of p38MAPK cascade 5.000E-7 1.731E-5 1.240E-4 3.635E-4 3 16
22 GO:0048679 regulation of axon regeneration 1.574E-6 5.201E-5 3.728E-4 1.144E-3 3 23
23 GO:0030878 thyroid gland development 2.593E-6 7.855E-5 5.629E-4 1.885E-3 3 27
24 GO:0070570 regulation of neuron projection regeneration 2.593E-6 7.855E-5 5.629E-4 1.885E-3 3 27
25 GO:1903800 positive regulation of production of miRNAs involved in gene silencing by miRNA 2.957E-6 8.598E-5 6.162E-4 2.150E-3 2 3
26 GO:1900744 regulation of p38MAPK cascade 3.592E-6 1.004E-4 7.199E-4 2.612E-3 3 30
27 GO:0038066 p38MAPK cascade 5.281E-6 1.422E-4 1.019E-3 3.839E-3 3 34
28 GO:0090170 regulation of Golgi inheritance 5.910E-6 1.534E-4 1.100E-3 4.296E-3 2 4
29 GO:1901214 regulation of neuron death 1.133E-5 2.784E-4 1.995E-3 8.240E-3 5 307
30 GO:0038095 Fc-epsilon receptor signaling pathway 1.149E-5 2.784E-4 1.995E-3 8.353E-3 4 142
31 GO:0035897 proteolysis in other organism 1.476E-5 3.461E-4 2.480E-3 1.073E-2 2 6
32 GO:0031103 axon regeneration 1.610E-5 3.658E-4 2.622E-3 1.171E-2 3 49
33 GO:0070997 neuron death 2.018E-5 4.289E-4 3.074E-3 1.467E-2 5 346
34 GO:0007256 activation of JNKK activity 2.065E-5 4.289E-4 3.074E-3 1.501E-2 2 7
35 GO:0060440 trachea formation 2.065E-5 4.289E-4 3.074E-3 1.501E-2 2 7
36 GO:0048538 thymus development 2.412E-5 4.871E-4 3.491E-3 1.753E-2 3 56
37 GO:0060324 face development 2.823E-5 5.547E-4 3.975E-3 2.052E-2 3 59
38 GO:0031102 neuron projection regeneration 2.970E-5 5.682E-4 4.072E-3 2.159E-2 3 60
39 GO:1903798 regulation of production of miRNAs involved in gene silencing by miRNA 3.535E-5 6.590E-4 4.723E-3 2.570E-2 2 9
40 GO:0060425 lung morphogenesis 3.956E-5 7.190E-4 5.153E-3 2.876E-2 3 66
41 GO:0070920 regulation of production of small RNA involved in gene silencing by RNA 4.416E-5 7.831E-4 5.612E-3 3.211E-2 2 10
42 GO:0038093 Fc receptor signaling pathway 4.948E-5 8.564E-4 6.138E-3 3.597E-2 4 206
43 GO:0060502 epithelial cell proliferation involved in lung morphogenesis 5.394E-5 9.120E-4 6.536E-3 3.922E-2 2 11
44 GO:0060439 trachea morphogenesis 6.469E-5 1.031E-3 7.392E-3 4.703E-2 2 12
45 GO:1903358 regulation of Golgi organization 6.469E-5 1.031E-3 7.392E-3 4.703E-2 2 12
46 GO:0048678 response to axon injury 6.526E-5 1.031E-3 7.392E-3 4.744E-2 3 78
47 GO:0050772 positive regulation of axonogenesis 7.039E-5 1.089E-3 7.803E-3
5.117E-2
 3 80
48 GO:2000637 positive regulation of gene silencing by miRNA 7.641E-5 1.157E-3 8.294E-3
5.555E-2
 2 13
49 GO:0043523 regulation of neuron apoptotic process 8.390E-5 1.245E-3 8.922E-3
6.100E-2
 4 236
50 GO:0048313 Golgi inheritance 8.909E-5 1.270E-3 9.101E-3
6.477E-2
 2 14
Show 45 more annotations

3: GO: Cellular Component [Display Chart] 19 input genes in category / 52 annotations before applied cutoff / 19061 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0008385 IkappaB kinase complex 5.150E-5 2.592E-3 1.176E-2 2.678E-3 2 11
2 GO:1902911 protein kinase complex 9.970E-5 2.592E-3 1.176E-2 5.184E-3 3 92
3 GO:0005925 focal adhesion 5.396E-4 6.169E-3 2.799E-2 2.806E-2 4 393
4 GO:0005924 cell-substrate adherens junction 5.659E-4 6.169E-3 2.799E-2 2.943E-2 4 398
5 GO:0030055 cell-substrate junction 5.931E-4 6.169E-3 2.799E-2 3.084E-2 4 403
6 GO:0005874 microtubule 7.305E-4 6.331E-3 2.873E-2 3.798E-2 4 426
7 GO:0005912 adherens junction 1.175E-3 8.730E-3 3.962E-2
6.111E-2
 4 484
8 GO:0061695 transferase complex, transferring phosphorus-containing groups 1.725E-3 1.121E-2
5.089E-2
8.971E-2
 3 244
9 GO:1902554 serine/threonine protein kinase complex 2.910E-3 1.681E-2
7.630E-2
1.513E-1
 2 81
10 GO:1990604 IRE1-TRAF2-ASK1 complex 3.982E-3 2.070E-2
9.396E-2
2.070E-1
 1 4
Show 5 more annotations

4: Human Phenotype [Display Chart] 10 input genes in category / 1559 annotations before applied cutoff / 4707 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 HP:0002212 Curly hair 6.846E-10 8.094E-7 6.418E-6 1.067E-6 5 25
2 HP:0001003 Multiple lentigines 1.038E-9 8.094E-7 6.418E-6 1.619E-6 5 27
3 HP:0000391 Thickened helices 3.036E-9 1.207E-6 9.567E-6 4.734E-6 5 33
4 HP:0001028 Hemangioma 4.245E-9 1.207E-6 9.567E-6 6.618E-6 7 156
5 HP:0000465 Webbed neck 4.619E-9 1.207E-6 9.567E-6 7.200E-6 6 82
6 HP:0100742 Vascular neoplasm 4.643E-9 1.207E-6 9.567E-6 7.239E-6 7 158
7 HP:0002967 Cubitus valgus 9.519E-9 2.120E-6 1.681E-5 1.484E-5 5 41
8 HP:0000293 Full cheeks 1.135E-8 2.213E-6 1.754E-5 1.770E-5 6 95
9 HP:0007440 Generalized hyperpigmentation 1.376E-8 2.383E-6 1.890E-5 2.145E-5 5 44
10 HP:0002002 Deep philtrum 1.546E-8 2.411E-6 1.912E-5 2.411E-5 5 45
11 HP:0006114 Multiple palmar creases 2.760E-8 3.586E-6 2.844E-5 4.303E-5 3 4
12 HP:0008113 Multiple plantar creases 2.760E-8 3.586E-6 2.844E-5 4.303E-5 3 4
13 HP:0001642 Pulmonic stenosis 3.435E-8 4.120E-6 3.267E-5 5.355E-5 6 114
14 HP:0006191 Deep palmar crease 3.924E-8 4.370E-6 3.465E-5 6.118E-5 4 19
15 HP:0001004 Lymphedema 4.788E-8 4.976E-6 3.946E-5 7.464E-5 5 56
16 HP:0004422 Biparietal narrowing 5.243E-8 5.109E-6 4.051E-5 8.174E-5 5 57
17 HP:0001048 Cavernous hemangioma 6.821E-8 5.635E-6 4.468E-5 1.063E-4 5 60
18 HP:0000917 Superior pectus carinatum 6.893E-8 5.635E-6 4.468E-5 1.075E-4 3 5
19 HP:0100703 Tongue thrusting 6.893E-8 5.635E-6 4.468E-5 1.075E-4 3 5
20 HP:0008391 Dystrophic fingernails 7.383E-8 5.635E-6 4.468E-5 1.151E-4 4 22
21 HP:0009553 Abnormality of the hairline 7.590E-8 5.635E-6 4.468E-5 1.183E-4 6 130
22 HP:0030141 Abnormality of the posterior hairline 9.488E-8 6.431E-6 5.100E-5 1.479E-4 5 64
23 HP:0002162 Low posterior hairline 9.488E-8 6.431E-6 5.100E-5 1.479E-4 5 64
24 HP:0011361 Congenital abnormal hair pattern 1.185E-7 7.699E-6 6.105E-5 1.848E-4 6 140
25 HP:0000915 Pectus excavatum of inferior sternum 1.377E-7 8.587E-6 6.809E-5 2.147E-4 3 6
26 HP:0100778 Cryoglobulinemia 1.503E-7 9.011E-6 7.145E-5 2.343E-4 4 26
27 HP:0000637 Long palpebral fissure 2.054E-7 1.186E-5 9.404E-5 3.202E-4 4 28
28 HP:0002576 Intussusception 2.380E-7 1.325E-5 1.051E-4 3.710E-4 4 29
29 HP:0001641 Abnormal pulmonary valve morphology 3.923E-7 2.070E-5 1.641E-4 6.115E-4 6 171
30 HP:0002217 Slow-growing hair 4.084E-7 2.070E-5 1.641E-4 6.367E-4 4 33
31 HP:0010788 Testicular neoplasm 4.249E-7 2.070E-5 1.641E-4 6.625E-4 5 86
32 HP:0100848 Neoplasm of the male external genitalia 4.249E-7 2.070E-5 1.641E-4 6.625E-4 5 86
33 HP:0011363 Abnormality of hair growth rate 5.215E-7 2.448E-5 1.941E-4 8.130E-4 4 35
34 HP:0002857 Genu valgum 5.649E-7 2.448E-5 1.941E-4 8.806E-4 5 91
35 HP:0009908 Anterior creases of earlobe 5.764E-7 2.448E-5 1.941E-4 8.987E-4 3 9
36 HP:0040170 Abnormality of hair growth 5.861E-7 2.448E-5 1.941E-4 9.137E-4 4 36
37 HP:0000280 Coarse facial features 5.874E-7 2.448E-5 1.941E-4 9.158E-4 6 183
38 HP:0001531 Failure to thrive in infancy 5.968E-7 2.448E-5 1.941E-4 9.304E-4 5 92
39 HP:0100538 Abnormality of the supraorbital ridges 6.301E-7 2.519E-5 1.997E-4 9.824E-4 5 93
40 HP:0004426 Abnormality of the cheek 8.057E-7 2.850E-5 2.260E-4 1.256E-3 6 193
41 HP:0005508 Monoclonal immunoglobulin M proteinemia 8.158E-7 2.850E-5 2.260E-4 1.272E-3 4 39
42 HP:0007392 Excessive wrinkled skin 8.158E-7 2.850E-5 2.260E-4 1.272E-3 4 39
43 HP:0031047 Paraproteinemia 8.158E-7 2.850E-5 2.260E-4 1.272E-3 4 39
44 HP:0002729 Follicular hyperplasia 8.158E-7 2.850E-5 2.260E-4 1.272E-3 4 39
45 HP:0001054 Numerous nevi 8.225E-7 2.850E-5 2.260E-4 1.282E-3 3 10
46 HP:0004482 Relative macrocephaly 9.055E-7 2.946E-5 2.336E-4 1.412E-3 4 40
47 HP:0000133 Gonadal dysgenesis 9.055E-7 2.946E-5 2.336E-4 1.412E-3 4 40
48 HP:0000380 Abnormality of the helix 9.071E-7 2.946E-5 2.336E-4 1.414E-3 5 100
49 HP:0040072 Abnormality of forearm bone 9.661E-7 3.074E-5 2.437E-4 1.506E-3 6 199
50 HP:0009811 Abnormality of the elbow 9.953E-7 3.103E-5 2.461E-4 1.552E-3 6 200
Show 45 more annotations

5: Mouse Phenotype [Display Chart] 18 input genes in category / 1229 annotations before applied cutoff / 10355 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 MP:0010322 increased cutaneous melanoma incidence 2.457E-7 3.019E-4 2.322E-3 3.019E-4 3 8
2 MP:0010275 increased melanoma incidence 9.609E-7 5.905E-4 4.542E-3 1.181E-3 3 12
3 MP:0030573 abnormal hair follicle cell proliferation 1.981E-6 8.115E-4 6.242E-3 2.435E-3 3 15
4 MP:0001215 skin hypoplasia 2.854E-6 8.769E-4 6.745E-3 3.508E-3 2 2
5 MP:0000858 altered metastatic potential 3.717E-6 9.137E-4 7.028E-3 4.568E-3 5 145
6 MP:0011862 decreased cranium length 4.936E-6 1.011E-3 7.777E-3 6.067E-3 3 20
7 MP:0010639 altered tumor pathology 7.635E-6 1.340E-3 1.031E-2 9.383E-3 6 299
8 MP:0008716 increased lung non-small cell carcinoma incidence 1.185E-5 1.696E-3 1.304E-2 1.457E-2 4 85
9 MP:0001272 increased metastatic potential 1.242E-5 1.696E-3 1.304E-2 1.526E-2 4 86
10 MP:0010283 decreased classified tumor incidence 1.406E-5 1.728E-3 1.329E-2 1.728E-2 3 28
11 MP:0011194 abnormal hair follicle physiology 1.739E-5 1.943E-3 1.494E-2 2.137E-2 3 30
12 MP:0008803 abnormal placental labyrinth vasculature morphology 2.258E-5 2.221E-3 1.708E-2 2.776E-2 4 100
13 MP:0001299 abnormal eye distance/ position 2.349E-5 2.221E-3 1.708E-2 2.887E-2 4 101
14 MP:0001188 hyperpigmentation 2.788E-5 2.417E-3 1.859E-2 3.427E-2 3 35
15 MP:0008714 increased lung carcinoma incidence 2.950E-5 2.417E-3 1.859E-2 3.625E-2 4 107
16 MP:0001722 pale yolk sac 3.408E-5 2.618E-3 2.014E-2 4.189E-2 4 111
17 MP:0030575 decreased hair follicle cell proliferation 5.963E-5 4.071E-3 3.131E-2
7.328E-2
 2 7
18 MP:0010945 lung epithelium hyperplasia 5.963E-5 4.071E-3 3.131E-2
7.328E-2
 2 7
19 MP:0004499 increased incidence of tumors by chemical induction 6.332E-5 4.096E-3 3.150E-2
7.782E-2
 4 130
20 MP:0003231 abnormal placenta vasculature 9.432E-5 5.796E-3 4.458E-2
1.159E-1
 4 144
21 MP:0010298 increased respiratory system tumor incidence 1.077E-4 5.910E-3 4.546E-2
1.323E-1
 4 149
22 MP:0008014 increased lung tumor incidence 1.077E-4 5.910E-3 4.546E-2
1.323E-1
 4 149
23 MP:0000097 short maxilla 1.154E-4 5.910E-3 4.546E-2
1.419E-1
 3 56
24 MP:0000460 mandible hypoplasia 1.154E-4 5.910E-3 4.546E-2
1.419E-1
 3 56
25 MP:0000275 heart hyperplasia 1.274E-4 6.262E-3 4.816E-2
1.565E-1
 2 10
26 MP:0002021 increased incidence of induced tumors 1.635E-4 7.160E-3
5.507E-2
2.010E-1
 4 166
27 MP:0000490 abnormal crypts of Lieberkuhn morphology 1.674E-4 7.160E-3
5.507E-2
2.057E-1
 4 167
28 MP:0010293 increased integument system tumor incidence 1.674E-4 7.160E-3
5.507E-2
2.057E-1
 4 167
29 MP:0006126 abnormal cardiac outflow tract development 1.752E-4 7.160E-3
5.507E-2
2.154E-1
 4 169
30 MP:0001273 decreased metastatic potential 1.801E-4 7.160E-3
5.507E-2
2.213E-1
 3 65
31 MP:0001213 abnormal skin cell number 1.864E-4 7.160E-3
5.507E-2
2.291E-1
 2 12
32 MP:0010346 increased thyroid carcinoma incidence 1.864E-4 7.160E-3
5.507E-2
2.291E-1
 2 12
33 MP:0009580 increased keratinocyte apoptosis 2.201E-4 8.197E-3
6.305E-2
2.705E-1
 2 13
34 MP:0004540 small maxilla 2.440E-4 8.821E-3
6.785E-2
2.999E-1
 3 72
35 MP:0001716 abnormal placenta labyrinth morphology 2.803E-4 9.841E-3
7.570E-2
3.445E-1
 4 191
36 MP:0012080 chylous ascites 2.957E-4 1.000E-2
7.694E-2
3.634E-1
 2 15
37 MP:0008721 abnormal chemokine level 3.093E-4 1.000E-2
7.694E-2
3.801E-1
 3 78
38 MP:0030386 facial bone hypoplasia 3.093E-4 1.000E-2
7.694E-2
3.801E-1
 3 78
39 MP:0005355 enlarged thyroid gland 3.376E-4 1.012E-2
7.783E-2
4.149E-1
 2 16
40 MP:0001721 absent visceral yolk sac blood islands 3.376E-4 1.012E-2
7.783E-2
4.149E-1
 2 16
41 MP:0010234 abnormal vibrissa follicle morphology 3.376E-4 1.012E-2
7.783E-2
4.149E-1
 2 16
42 MP:0010300 increased skin tumor incidence 4.267E-4 1.220E-2
9.382E-2
5.244E-1
 3 87
43 MP:0009905 absent tongue 4.295E-4 1.220E-2
9.382E-2
5.279E-1
 2 18
44 MP:0002018 increased malignant tumor incidence 4.367E-4 1.220E-2
9.382E-2
5.367E-1
 5 393
45 MP:0001302 eyelids open at birth 4.562E-4 1.228E-2
9.444E-2
5.606E-1
 3 89
46 MP:0000511 abnormal intestinal mucosa morphology 4.637E-4 1.228E-2
9.444E-2
5.698E-1
 4 218
47 MP:0001201 translucent skin 4.796E-4 1.228E-2
9.444E-2
5.894E-1
 2 19
48 MP:0005426 tachypnea 4.796E-4 1.228E-2
9.444E-2
5.894E-1
 2 19
49 MP:0002026 increased leukemia incidence 5.028E-4 1.261E-2
9.700E-2
6.180E-1
 3 92
50 MP:0011205 excessive folding of visceral yolk sac 5.323E-4 1.306E-2
1.004E-1
6.542E-1
 2 20
Show 45 more annotations

6: Domain [Display Chart] 19 input genes in category / 107 annotations before applied cutoff / 18735 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 PS00107 PROTEIN KINASE ATP PROSITE 1.179E-23 9.435E-22 4.958E-21 1.261E-21 16 459
2 IPR000719 Prot kinase dom InterPro 3.285E-23 9.435E-22 4.958E-21 3.515E-21 16 489
3 PS50011 PROTEIN KINASE DOM PROSITE 3.747E-23 9.435E-22 4.958E-21 4.010E-21 16 493
4 IPR008271 Ser/Thr kinase AS InterPro 4.281E-23 9.435E-22 4.958E-21 4.580E-21 15 357
5 SM00220 S TKc SMART 4.661E-23 9.435E-22 4.958E-21 4.987E-21 15 359
6 PS00108 PROTEIN KINASE ST PROSITE 5.291E-23 9.435E-22 4.958E-21 5.661E-21 15 362
7 PF00069 Pkinase Pfam 1.731E-20 2.646E-19 1.391E-18 1.852E-18 14 381
8 IPR017441 Protein kinase ATP BS InterPro 1.753E-16 2.345E-15 1.232E-14 1.876E-14 12 379
9 PF07714 Pkinase Tyr Pfam 2.929E-11 3.482E-10 1.830E-9 3.134E-9 7 129
10 IPR001245 Ser-Thr/Tyr kinase cat dom InterPro 4.723E-11 5.054E-10 2.656E-9 5.054E-9 7 138
11 IPR017419 MAP3K12 MAP3K13 InterPro 9.744E-7 9.478E-6 4.981E-5 1.043E-4 2 2
12 IPR015785 MAP3K10 InterPro 5.839E-6 4.806E-5 2.526E-4 6.248E-4 2 4
13 IPR016231 MLK1/MLK2/MLK4 InterPro 5.839E-6 4.806E-5 2.526E-4 6.248E-4 2 4
14 PF00564 PB1 Pfam 8.803E-5 5.541E-4 2.911E-3 9.419E-3 2 14
15 IPR000270 PB1 dom InterPro 8.803E-5 5.541E-4 2.911E-3 9.419E-3 2 14
16 SM00666 PB1 SMART 8.803E-5 5.541E-4 2.911E-3 9.419E-3 2 14
17 PS51745 PB1 PROSITE 8.803E-5 5.541E-4 2.911E-3 9.419E-3 2 14
18 PS51421 RAS PROSITE 5.683E-4 3.378E-3 1.775E-2
6.081E-2
 2 35
19 IPR020849 Small GTPase Ras InterPro 6.354E-4 3.578E-3 1.880E-2
6.798E-2
 2 37
20 IPR027257 MAPKKK12 InterPro 1.014E-3 4.341E-3 2.281E-2
1.085E-1
 1 1
21 IPR017421 MAPKKK7 InterPro 1.014E-3 4.341E-3 2.281E-2
1.085E-1
 1 1
22 IPR027258 MAPKKK13 InterPro 1.014E-3 4.341E-3 2.281E-2
1.085E-1
 1 1
23 IPR032022 NUDIX InterPro 1.014E-3 4.341E-3 2.281E-2
1.085E-1
 1 1
24 PF16705 NUDIX 5 Pfam 1.014E-3 4.341E-3 2.281E-2
1.085E-1
 1 1
25 IPR017424 MAPKKK8 InterPro 1.014E-3 4.341E-3 2.281E-2
1.085E-1
 1 1
26 PF14604 SH3 9 Pfam 2.795E-3 1.150E-2
6.044E-2
2.990E-1
 2 78
27 IPR025136 DUF4071 InterPro 3.040E-3 1.162E-2
6.103E-2
3.252E-1
 1 3
28 PF13281 DUF4071 Pfam 3.040E-3 1.162E-2
6.103E-2
3.252E-1
 1 3
29 PF07653 SH3 2 Pfam 3.463E-3 1.184E-2
6.222E-2
3.705E-1
 2 87
30 IPR011511 SH3 2 InterPro 3.463E-3 1.184E-2
6.222E-2
3.705E-1
 2 87
31 SM00219 TyrKc SMART 3.541E-3 1.184E-2
6.222E-2
3.789E-1
 2 88
32 IPR020635 Tyr kinase cat dom InterPro 3.541E-3 1.184E-2
6.222E-2
3.789E-1
 2 88
33 PF02196 RBD Pfam 6.070E-3 1.941E-2
1.020E-1
6.495E-1
 1 6
34 IPR013761 SAM/pointed InterPro 6.169E-3 1.941E-2
1.020E-1
6.601E-1
 2 117
35 SM00455 RBD SMART 7.079E-3 1.993E-2
1.047E-1
7.574E-1
 1 7
36 PF04434 SWIM Pfam 7.079E-3 1.993E-2
1.047E-1
7.574E-1
 1 7
37 IPR003116 RBD dom InterPro 7.079E-3 1.993E-2
1.047E-1
7.574E-1
 1 7
38 PS50898 RBD PROSITE 7.079E-3 1.993E-2
1.047E-1
7.574E-1
 1 7
39 PF00071 Ras Pfam 8.250E-3 2.263E-2
1.189E-1
8.827E-1
 2 136
40 IPR007527 Znf SWIM InterPro 9.092E-3 2.373E-2
1.247E-1
9.729E-1
 1 9
41 PS50966 ZF SWIM PROSITE 9.092E-3 2.373E-2
1.247E-1
9.729E-1
 1 9
42 IPR001806 Small GTPase InterPro 1.127E-2 2.796E-2
1.469E-1
1.000E0
 2 160
43 PF00018 SH3 1 Pfam 1.181E-2 2.796E-2
1.469E-1
1.000E0
 2 164
44 IPR005225 Small GTP-bd dom InterPro 1.223E-2 2.796E-2
1.469E-1
1.000E0
 2 167
45 PS51550 EPH LBD PROSITE 1.411E-2 2.796E-2
1.469E-1
1.000E0
 1 14
46 IPR027936 Eph TM InterPro 1.411E-2 2.796E-2
1.469E-1
1.000E0
 1 14
47 PS00790 RECEPTOR TYR KIN V 1 PROSITE 1.411E-2 2.796E-2
1.469E-1
1.000E0
 1 14
48 IPR001090 Ephrin rcpt lig-bd dom InterPro 1.411E-2 2.796E-2
1.469E-1
1.000E0
 1 14
49 SM00615 EPH lbd SMART 1.411E-2 2.796E-2
1.469E-1
1.000E0
 1 14
50 PF01404 Ephrin lbd Pfam 1.411E-2 2.796E-2
1.469E-1
1.000E0
 1 14
Show 45 more annotations

7: Pathway [Display Chart] 19 input genes in category / 431 annotations before applied cutoff / 12450 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 M13863 MAPKinase Signaling Pathway MSigDB C2 BIOCARTA (v6.0) 2.500E-27 1.077E-24 7.158E-24 1.077E-24 14 87
2 83048 MAPK signaling pathway BioSystems: KEGG 5.496E-25 1.184E-22 7.869E-22 2.369E-22 16 255
3 PW:0000313 c-Jun N-terminal kinases MAPK signaling Pathway Ontology 1.645E-22 2.363E-20 1.570E-19 7.089E-20 10 31
4 M3721 JNK MAPK Pathway MSigDB C2 BIOCARTA (v6.0) 3.125E-21 3.367E-19 2.237E-18 1.347E-18 10 40
5 137943 p38 MAPK signaling pathway BioSystems: Pathway Interaction Database 8.406E-15 7.246E-13 4.814E-12 3.623E-12 7 29
6 83091 GnRH signaling pathway BioSystems: KEGG 4.610E-13 3.311E-11 2.200E-10 1.987E-10 8 92
7 1269286 RAF activation BioSystems: REACTOME 9.144E-13 5.630E-11 3.741E-10 3.941E-10 6 25
8 P00018 EGF receptor signaling pathway PantherDB 2.154E-12 1.160E-10 7.711E-10 9.284E-10 8 111
9 101143 Neurotrophin signaling pathway BioSystems: KEGG 3.802E-12 1.821E-10 1.210E-9 1.639E-9 8 119
10 P04393 Ras Pathway PantherDB 5.052E-12 2.177E-10 1.447E-9 2.177E-9 7 68
11 1457784 Signaling by moderate kinase activity BRAF mutants BioSystems: REACTOME 1.664E-11 5.975E-10 3.970E-9 7.170E-9 6 39
12 1457785 Paradoxical activation of RAF signaling by kinase inactive BRAF BioSystems: REACTOME 1.664E-11 5.975E-10 3.970E-9 7.170E-9 6 39
13 P00034 Integrin signalling pathway PantherDB 5.906E-11 1.958E-9 1.301E-8 2.545E-8 8 167
14 1457782 Signaling by RAS mutants BioSystems: REACTOME 9.084E-11 2.686E-9 1.785E-8 3.915E-8 6 51
15 P00021 FGF signaling pathway PantherDB 9.349E-11 2.686E-9 1.785E-8 4.030E-8 7 102
16 PW:0000102 The extracellular signal-regulated RAF/MEK/ERK signaling Pathway Ontology 3.011E-10 8.111E-9 5.389E-8 1.298E-7 5 26
17 83112 Thyroid cancer BioSystems: KEGG 5.421E-10 1.374E-8 9.132E-8 2.336E-7 5 29
18 1457781 Oncogenic MAPK signaling BioSystems: REACTOME 1.078E-9 2.582E-8 1.716E-7 4.647E-7 6 76
19 1457783 Signaling by high-kinase activity BRAF mutants BioSystems: REACTOME 1.474E-9 3.343E-8 2.221E-7 6.351E-7 5 35
20 1269287 MAP2K and MAPK activation BioSystems: REACTOME 2.604E-9 5.611E-8 3.728E-7 1.122E-6 5 39
21 1269288 Negative regulation of MAPK pathway BioSystems: REACTOME 2.973E-9 6.101E-8 4.054E-7 1.281E-6 5 40
22 83115 Bladder cancer BioSystems: KEGG 3.382E-9 6.626E-8 4.403E-7 1.458E-6 5 41
23 83080 T cell receptor signaling pathway BioSystems: KEGG 6.883E-9 1.290E-7 8.570E-7 2.967E-6 6 103
24 83109 Endometrial cancer BioSystems: KEGG 9.483E-9 1.703E-7 1.131E-6 4.087E-6 5 50
25 868086 Rap1 signaling pathway BioSystems: KEGG 1.492E-8 2.569E-7 1.707E-6 6.429E-6 7 210
26 83117 Acute myeloid leukemia BioSystems: KEGG 1.550E-8 2.569E-7 1.707E-6 6.679E-6 5 55
27 83119 Non-small cell lung cancer BioSystems: KEGG 2.035E-8 3.133E-7 2.082E-6 8.772E-6 5 58
28 P00010 B cell activation PantherDB 2.035E-8 3.133E-7 2.082E-6 8.772E-6 5 58
29 83086 Long-term depression BioSystems: KEGG 2.421E-8 3.499E-7 2.325E-6 1.044E-5 5 60
30 P00047 PDGF signaling pathway PantherDB 2.435E-8 3.499E-7 2.325E-6 1.050E-5 6 127
31 1457786 Signaling by BRAF and RAF fusions BioSystems: REACTOME 2.635E-8 3.664E-7 2.434E-6 1.136E-5 5 61
32 83110 Glioma BioSystems: KEGG 3.368E-8 4.536E-7 3.014E-6 1.451E-5 5 64
33 83107 Renal cell carcinoma BioSystems: KEGG 3.645E-8 4.761E-7 3.163E-6 1.571E-5 5 65
34 1269298 Fc epsilon receptor (FCERI) signaling BioSystems: REACTOME 4.022E-8 5.099E-7 3.388E-6 1.734E-5 8 381
35 83085 Long-term potentiation BioSystems: KEGG 4.254E-8 5.238E-7 3.481E-6 1.833E-5 5 67
36 83114 Melanoma BioSystems: KEGG 4.941E-8 5.915E-7 3.930E-6 2.129E-5 5 69
37 83116 Chronic myeloid leukemia BioSystems: KEGG 5.713E-8 6.655E-7 4.422E-6 2.462E-5 5 71
38 1269289 Negative feedback regulation of MAPK pathway BioSystems: REACTOME 6.010E-8 6.816E-7 4.529E-6 2.590E-5 3 6
39 P00053 T cell activation PantherDB 8.069E-8 8.917E-7 5.925E-6 3.478E-5 5 76
40 1269299 FCERI mediated MAPK activation BioSystems: REACTOME 9.309E-8 1.003E-6 6.665E-6 4.012E-5 7 274
41 1404798 EGFR tyrosine kinase inhibitor resistance BioSystems: KEGG 9.815E-8 1.032E-6 6.856E-6 4.230E-5 5 79
42 M4910 ERK1/ERK2 MAPK Pathway MSigDB C2 BIOCARTA (v6.0) 1.356E-7 1.391E-6 9.245E-6 5.844E-5 4 32
43 83049 ErbB signaling pathway BioSystems: KEGG 1.507E-7 1.510E-6 1.003E-5 6.494E-5 5 86
44 83111 Prostate cancer BioSystems: KEGG 1.597E-7 1.564E-6 1.040E-5 6.884E-5 5 87
45 83072 Gap junction BioSystems: KEGG 1.692E-7 1.620E-6 1.077E-5 7.292E-5 5 88
46 P05918 p38 MAPK pathway PantherDB 2.212E-7 2.073E-6 1.377E-5 9.536E-5 4 36
47 M12012 p38 MAPK Pathway MSigDB C2 BIOCARTA (v6.0) 2.478E-7 2.273E-6 1.510E-5 1.068E-4 4 37
48 1404799 Endocrine resistance BioSystems: KEGG 2.620E-7 2.352E-6 1.563E-5 1.129E-4 5 96
49 138057 ErbB1 downstream signaling BioSystems: Pathway Interaction Database 3.550E-7 3.122E-6 2.075E-5 1.530E-4 5 102
50 137921 Ras signaling in the CD4+ TCR pathway BioSystems: Pathway Interaction Database 4.934E-7 4.253E-6 2.826E-5 2.127E-4 3 11
Show 45 more annotations

8: Pubmed [Display Chart] 19 input genes in category / 8040 annotations before applied cutoff / 38193 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 18855897 MAP3Ks as central regulators of cell fate during development. Pubmed 5.082E-32 4.086E-28 3.910E-27 4.086E-28 10 14
2 20936779 A human MAP kinase interactome. Pubmed 8.464E-15 3.403E-11 3.256E-10 6.805E-11 10 486
3 17366577 Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Pubmed 4.372E-14 5.022E-11 4.806E-10 3.515E-10 4 4
4 17704260 Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. Pubmed 4.372E-14 5.022E-11 4.806E-10 3.515E-10 4 4
5 22946697 Craniofacial and dental development in cardio-facio-cutaneous syndrome: the importance of Ras signaling homeostasis. Pubmed 4.372E-14 5.022E-11 4.806E-10 3.515E-10 4 4
6 20301365 Cardiofaciocutaneous Syndrome Pubmed 4.372E-14 5.022E-11 4.806E-10 3.515E-10 4 4
7 21447798 Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Pubmed 4.372E-14 5.022E-11 4.806E-10 3.515E-10 4 4
8 10712923 The Ras branch of small GTPases: Ras family members don't fall far from the tree. Pubmed 5.142E-14 5.167E-11 4.945E-10 4.134E-10 5 15
9 9069267 Signal transduction by the neurotrophin receptors. Pubmed 1.466E-13 1.309E-10 1.253E-9 1.178E-9 5 18
10 22773810 Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Pubmed 2.186E-13 1.757E-10 1.682E-9 1.757E-9 4 5
11 19681119 RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Pubmed 6.555E-13 4.791E-10 4.585E-9 5.270E-9 4 6
12 20302979 Investigation of gene dosage imbalances in patients with Noonan syndrome using multiplex ligation-dependent probe amplification analysis. Pubmed 1.529E-12 9.094E-10 8.703E-9 1.229E-8 4 7
13 19206169 Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Pubmed 1.529E-12 9.094E-10 8.703E-9 1.229E-8 4 7
14 17192257 Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Pubmed 1.584E-12 9.094E-10 8.703E-9 1.273E-8 6 78
15 20301303 Noonan Syndrome Pubmed 3.057E-12 1.536E-9 1.470E-8 2.458E-8 4 8
16 21514245 c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Pubmed 3.057E-12 1.536E-9 1.470E-8 2.458E-8 4 8
17 25241761 Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network. Pubmed 5.062E-12 2.394E-9 2.291E-8 4.070E-8 8 371
18 15866172 Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Pubmed 5.501E-12 2.457E-9 2.351E-8 4.423E-8 4 9
19 23760366 The TGFβ-induced phosphorylation and activation of p38 mitogen-activated protein kinase is mediated by MAP3K4 and MAP3K10 but not TAK1. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
20 28249840 New Guideline on Managing Colorectal Cancer. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
21 25600339 Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
22 27815357 Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
23 21305640 Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
24 16737746 The expression of the homologue of the Caenorhabditis elegans lin-45 raf is regulated in the motile stages of the plant parasitic nematode Meloidogyne artiellia. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
25 27382031 Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
26 25164765 Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
27 25463315 Is diagnosing cardio-facio-cutaneous (CFC) syndrome still a challenge? Delineation of the phenotype in 15 Polish patients with proven mutations, including novel mutations in the BRAF1 gene. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
28 27634910 Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
29 24859998 KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
30 24024839 Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
31 27916952 High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
32 28091917 Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
33 25666295 FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
34 26989027 Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
35 24806883 Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
36 26090869 Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
37 28074351 KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
38 18413255 Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
39 18060073 Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
40 25722381 A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)â? . Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
41 16439621 Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
42 22427190 Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
43 27636997 Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
44 29335867 Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
45 18945298 RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Pubmed 1.044E-10 1.865E-8 1.784E-7 8.391E-7 3 3
46 27737711 Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. Pubmed 4.173E-10 5.412E-8 5.179E-7 3.355E-6 3 4
47 20098682 Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. Pubmed 4.173E-10 5.412E-8 5.179E-7 3.355E-6 3 4
48 19765726 Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. Pubmed 4.173E-10 5.412E-8 5.179E-7 3.355E-6 3 4
49 25886136 A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Pubmed 4.173E-10 5.412E-8 5.179E-7 3.355E-6 3 4
50 28025078 Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. Pubmed 4.173E-10 5.412E-8 5.179E-7 3.355E-6 3 4
Show 45 more annotations

9: Interaction [Display Chart] 19 input genes in category / 1365 annotations before applied cutoff / 17703 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 int:MAP2K7 MAP2K7 interactions 8.466E-23 1.156E-19 9.010E-19 1.156E-19 11 68
2 int:MAP2K4 MAP2K4 interactions 1.725E-21 1.177E-18 9.178E-18 2.354E-18 10 52
3 int:MAP2K1 MAP2K1 interactions 1.168E-12 5.313E-10 4.142E-9 1.594E-9 8 145
4 int:MAP2K6 MAP2K6 interactions 6.646E-12 2.268E-9 1.768E-8 9.072E-9 6 47
5 int:MAP2K3 MAP2K3 interactions 3.276E-11 8.944E-9 6.973E-8 4.472E-8 7 124
6 int:RAF1 RAF1 interactions 4.973E-11 1.131E-8 8.821E-8 6.788E-8 8 231
7 int:MAPK8IP1 MAPK8IP1 interactions 5.163E-10 1.007E-7 7.849E-7 7.047E-7 5 40
8 int:TRAF6 TRAF6 interactions 1.836E-9 3.132E-7 2.442E-6 2.506E-6 8 364
9 int:CHUK CHUK interactions 1.221E-8 1.852E-6 1.444E-5 1.667E-5 6 160
10 int:MAPK1 MAPK1 interactions 3.821E-8 5.216E-6 4.067E-5 5.216E-5 7 341
11 int:MAPK8 MAPK8 interactions 6.732E-8 8.354E-6 6.513E-5 9.190E-5 6 213
12 int:MAPK8IP3 MAPK8IP3 interactions 1.139E-7 1.295E-5 1.010E-4 1.554E-4 4 43
13 int:ARAF ARAF interactions 1.304E-7 1.369E-5 1.067E-4 1.780E-4 5 118
14 int:MAP3K3 MAP3K3 interactions 4.154E-7 4.050E-5 3.158E-4 5.670E-4 4 59
15 int:BRAF BRAF interactions 4.919E-7 4.476E-5 3.490E-4 6.714E-4 5 154
16 int:IKBKB IKBKB interactions 8.506E-7 7.257E-5 5.658E-4 1.161E-3 5 172
17 int:HSP90AB1 HSP90AB1 interactions 2.341E-6 1.880E-4 1.466E-3 3.195E-3 6 390
18 int:SH3RF1 SH3RF1 interactions 3.763E-6 2.854E-4 2.225E-3 5.136E-3 3 29
19 int:MAP3K5 MAP3K5 interactions 4.559E-6 3.275E-4 2.554E-3 6.223E-3 4 107
20 int:RAC1 RAC1 interactions 5.337E-6 3.643E-4 2.840E-3 7.285E-3 5 250
21 int:CDC37 CDC37 interactions 6.706E-6 4.359E-4 3.398E-3 9.154E-3 5 262
22 int:MAP3K11 MAP3K11 interactions 1.010E-5 6.193E-4 4.828E-3 1.378E-2 3 40
23 int:AXIN1 AXIN1 interactions 1.049E-5 6.193E-4 4.828E-3 1.433E-2 4 132
24 int:MAP3K2 MAP3K2 interactions 1.089E-5 6.193E-4 4.828E-3 1.486E-2 3 41
25 int:TRAF3 TRAF3 interactions 1.362E-5 7.437E-4 5.798E-3 1.859E-2 4 141
26 int:RCE1 RCE1 interactions 1.633E-5 8.560E-4 6.674E-3 2.229E-2 2 6
27 int:PPP6C PPP6C interactions 1.693E-5 8.560E-4 6.674E-3 2.311E-2 4 149
28 int:STK11 STK11 interactions 1.784E-5 8.699E-4 6.782E-3 2.436E-2 4 151
29 int:IGF1R IGF1R interactions 2.029E-5 9.548E-4 7.444E-3 2.769E-2 4 156
30 int:PPM1L PPM1L interactions 2.284E-5 1.006E-3 7.843E-3 3.118E-2 2 7
31 int:ARHGAP4 ARHGAP4 interactions 2.284E-5 1.006E-3 7.843E-3 3.118E-2 2 7
32 int:MAP3K7 MAP3K7 interactions 2.469E-5 1.039E-3 8.099E-3 3.370E-2 4 164
33 int:MAP2K2 MAP2K2 interactions 2.511E-5 1.039E-3 8.099E-3 3.428E-2 3 54
34 int:NFKBIA NFKBIA interactions 2.714E-5 1.090E-3 8.494E-3 3.704E-2 4 168
35 int:TRIM5 TRIM5 interactions 2.803E-5 1.093E-3 8.522E-3 3.826E-2 3 56
36 int:MAP2K5 MAP2K5 interactions 2.956E-5 1.121E-3 8.740E-3 4.036E-2 3 57
37 int:RASGRP2 RASGRP2 interactions 3.044E-5 1.123E-3 8.755E-3 4.155E-2 2 8
38 int:TRAF2 TRAF2 interactions 3.322E-5 1.193E-3 9.303E-3 4.534E-2 5 365
39 int:AKT1 AKT1 interactions 4.728E-5 1.627E-3 1.268E-2
6.453E-2
 5 393
40 int:KIF17 KIF17 interactions 4.886E-5 1.627E-3 1.268E-2
6.669E-2
 2 10
41 int:KSR2 KSR2 interactions 4.886E-5 1.627E-3 1.268E-2
6.669E-2
 2 10
42 int:ALK ALK interactions 5.483E-5 1.782E-3 1.389E-2
7.484E-2
 3 70
43 int:ABCB5 ABCB5 interactions 5.968E-5 1.845E-3 1.438E-2
8.146E-2
 2 11
44 int:PREX1 PREX1 interactions 5.968E-5 1.845E-3 1.438E-2
8.146E-2
 2 11
45 int:YWHAB YWHAB interactions 6.125E-5 1.845E-3 1.438E-2
8.361E-2
 5 415
46 int:WNK1 WNK1 interactions 6.217E-5 1.845E-3 1.438E-2
8.486E-2
 3 73
47 int:NEDD4L NEDD4L interactions 6.979E-5 2.027E-3 1.580E-2
9.526E-2
 4 214
48 int:RAP1B RAP1B interactions 7.578E-5 2.155E-3 1.680E-2
1.034E-1
 3 78
49 int:YWHAG YWHAG interactions 8.525E-5 2.375E-3 1.852E-2
1.164E-1
 5 445
50 int:PTPN11 PTPN11 interactions 9.075E-5 2.477E-3 1.932E-2
1.239E-1
 4 229
Show 45 more annotations

10: Cytoband [Display Chart] 19 input genes in category / 19 annotations before applied cutoff / 34661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 15q22.1-q22.33 15q22.1-q22.33 5.482E-4 1.041E-2 3.694E-2 1.042E-2 1 1
2 11q13.1-q13.3 11q13.1-q13.3 1.096E-3 1.041E-2 3.694E-2 2.082E-2 1 2
3 7q21.2 7q21.2 8.737E-3 3.099E-2
1.099E-1
1.660E-1
 1 16
4 6q26 6q26 9.824E-3 3.099E-2
1.099E-1
1.866E-1
 1 18
5 6q22.33 6q22.33 1.037E-2 3.099E-2
1.099E-1
1.970E-1
 1 19
6 10p11.23 10p11.23 1.145E-2 3.099E-2
1.099E-1
2.176E-1
 1 21
7 3q27 3q27 1.362E-2 3.099E-2
1.099E-1
2.588E-1
 1 25
8 2q14.3 2q14.3 1.524E-2 3.099E-2
1.099E-1
2.896E-1
 1 28
9 17q23.3 17q23.3 1.632E-2 3.099E-2
1.099E-1
3.101E-1
 1 30
10 12p12.1 12p12.1 1.632E-2 3.099E-2
1.099E-1
3.101E-1
 1 30
11 6q15 6q15 1.794E-2 3.099E-2
1.099E-1
3.409E-1
 1 33
12 1p13.2 1p13.2 2.546E-2 4.031E-2
1.430E-1
4.837E-1
 1 47
13 1p36 1p36 2.813E-2 4.035E-2
1.431E-1
5.345E-1
 1 52
14 5q11.2 5q11.2 2.973E-2 4.035E-2
1.431E-1
5.649E-1
 1 55
15 12q13 12q13 3.822E-2 4.841E-2
1.718E-1
7.262E-1
 1 71
Show 10 more annotations

11: Transcription Factor Binding Site [Display Chart] 14 input genes in category / 230 annotations before applied cutoff / 9770 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 V$CREB Q4 V$CREB Q4 1.538E-4 1.907E-2
1.148E-1
 3.538E-2 4 203
2 V$CREB Q2 V$CREB Q2 1.659E-4 1.907E-2
1.148E-1
 3.815E-2 4 207

12: Gene Family [Display Chart] 19 input genes in category / 10 annotations before applied cutoff / 18194 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 654 Mitogen-activated protein kinase kinase kinases genenames.org 1.763E-35 1.763E-34 5.165E-34 1.763E-34 13 24
2 653 Mitogen-activated protein kinase kinases genenames.org 2.163E-5 1.082E-4 3.168E-4 2.163E-4 2 7
3 389 RAS type GTPase family genenames.org 4.718E-4 1.573E-3 4.607E-3 4.718E-3 2 31
4 1157 Mitogen-activated protein kinase kinase kinases|RAF family genenames.org 5.211E-3 1.303E-2 3.816E-2
5.211E-2
 1 5
5 90 Zinc fingers SWIM-type genenames.org 9.362E-3 1.872E-2
5.484E-2
9.362E-2
 1 9
6 1095 Fibronectin type III domain containing|Sterile alpha motif domain containing|EPH receptors genenames.org 1.453E-2 2.421E-2
7.091E-2
1.453E-1
 1 14
Show 1 more annotation

13: Coexpression [Display Chart] 19 input genes in category / 1884 annotations before applied cutoff / 23137 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 12471243-TableS2 Human Manning02 624genes ProteinKinases GeneSigDB 9.996E-18 1.883E-14 1.529E-13 1.883E-14 12 368
2 20460173-ImmPortNaturalKillerCellCytotoxicity Human Immune Kong10 135genes ImmPort NaturalKillerCellCytotoxicity GeneSigDB 4.837E-8 4.556E-5 3.699E-4 9.113E-5 5 126
3 20553613-AF-1 Human pancreas Kalinina03 66genes GeneSigDB 1.758E-7 1.104E-4 8.961E-4 3.311E-4 4 62
4 M2474 Genes up-regulated in BEAS-2B cells (bronchial epithelium) stimulated with IL13 [GeneID=3596] on days 1 to 3 and then rested for the next 3 days (repeated-stimulation or memory model) MSigDB C2: CGP Curated Gene Sets (v6.0) 3.169E-7 1.493E-4 1.212E-3 5.971E-4 3 17
5 M1489 Genes required for CTNNB1 [GeneID=1499] activity in DLD-1 cell (colon cancer with APC [GeneID=324] deletions), based on shRNA screen. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.522E-6 9.489E-4 7.704E-3 4.751E-3 3 33
6 15548366-Table3 Mouse Bladder Yao04 37genes GeneSigDB 3.022E-6 9.489E-4 7.704E-3 5.694E-3 3 35
7 18339850-Table1 Human Lung Tessema08 43genes GeneSigDB 5.282E-6 1.422E-3 1.154E-2 9.951E-3 3 42
8 M14019 The lung adenocarcinoma TSP (tumor sequencing project) genes bearing recurrent somatic mutations. MSigDB C2: CGP Curated Gene Sets (v6.0) 9.565E-6 2.117E-3 1.719E-2 1.802E-2 2 6
9 20036005-Table3 Human Leukemia Tavolaro10 56genes GeneSigDB 1.011E-5 2.117E-3 1.719E-2 1.906E-2 3 52
10 15897243-Table1 Human Lymphoma Zhu05 61genes GeneSigDB 1.134E-5 2.137E-3 1.735E-2 2.137E-2 3 54
11 18260157-Table4 Human Brain Ruano08 7genes GeneSigDB 1.338E-5 2.292E-3 1.861E-2 2.522E-2 2 7
12 16254190-Table3 Mouse Skin Zhang05 80genes GeneSigDB 3.178E-5 4.989E-3 4.050E-2
5.987E-2
 3 76
13 19286929-SuppTable2n Mouse Lung Rangasamy09 254genes GeneSigDB 3.809E-5 5.521E-3 4.482E-2
7.177E-2
 4 239
14 M9869 Genes up-regulated in primary granulosa cells in response to forskolin [PubChem=47936]. MSigDB C2: CGP Curated Gene Sets (v6.0) 5.272E-5 6.844E-3
5.556E-2
9.932E-2
 3 90
15 M16587 Genes up-regulated in primary granulosa cells after stimulation with LH or FSH gonadotrophic hormones for 24 h. MSigDB C2: CGP Curated Gene Sets (v6.0) 5.449E-5 6.844E-3
5.556E-2
1.027E-1
 3 91
16 16243790-Table4 Human Leukemia Chiaretti05 16genes GeneSigDB 6.666E-5 7.849E-3
6.372E-2
1.256E-1
 2 15
17 16433906-Table1 Human Prostate Davis06 28genes GeneSigDB 1.744E-4 1.933E-2
1.570E-1
3.287E-1
 2 24
18 15475428-Table4 Human Breast Modlich04 25genes GeneSigDB 1.895E-4 1.984E-2
1.610E-1
3.571E-1
 2 25
19 M16488 The lung adenocarcinoma TSP (tumor sequencing project) genes that were found significantly mutated by at least one method. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.052E-4 2.035E-2
1.652E-1
3.866E-1
 2 26
20 16322222-Table2 Human Breast Mazurek05 28genes GeneSigDB 2.215E-4 2.087E-2
1.694E-1
4.174E-1
 2 27
21 15140256-Table1 Human Colon VanErk04 36genes GeneSigDB 2.741E-4 2.384E-2
1.935E-1
5.165E-1
 2 30
22 18519693-Table1 Human StemCell Mishra08 289genes GeneSigDB 4.228E-4 2.384E-2
1.935E-1
7.966E-1
 3 182
23 19129520-TableS27 Human StemCell Mullighan09 39genes GeneSigDB 4.413E-4 2.384E-2
1.935E-1
8.314E-1
 2 38
24 18316601-Table1 Human Breast Rizki08 204genes GeneSigDB 5.406E-4 2.384E-2
1.935E-1
1.000E0
 3 198
25 M8400 Genes down-regulated in brain microglia versus spleen CD8- dendritic cells. MSigDB C7: Immunologic Signatures (v6.0) 5.406E-4 2.384E-2
1.935E-1
1.000E0
 3 198
26 M5346 Genes down-regulated in comparison of control polymorphonuclear leukocytes (PMN) at 0 h versus PMN treated with F. tularensis vaccine at 6 h. MSigDB C7: Immunologic Signatures (v6.0) 5.406E-4 2.384E-2
1.935E-1
1.000E0
 3 198
27 M9635 Genes up-regulated in CD4 [GeneID=920] T helper cells (1h): Th0 versus TGFB1 and IL6 [GeneID=7040;3569]. MSigDB C7: Immunologic Signatures (v6.0) 5.486E-4 2.384E-2
1.935E-1
1.000E0
 3 199
28 M8723 Genes down-regulated in bone marrow-derived macrophages treated with LPS for 2h: heterozygous versus homozygous knockout of MLL4 [GeneID=9757]. MSigDB C7: Immunologic Signatures (v6.0) 5.486E-4 2.384E-2
1.935E-1
1.000E0
 3 199
29 M9915 Genes up-regulated in B lymphocytes: untreated versus anti-IgM for 3h. MSigDB C7: Immunologic Signatures (v6.0) 5.486E-4 2.384E-2
1.935E-1
1.000E0
 3 199
30 M8158 Genes up-regulated in HEK293 cells expressing mutant NOD2 [GeneID=64127]: untreated versus muramyl dipeptide [PubChem=11620162] for 2h. MSigDB C7: Immunologic Signatures (v6.0) 5.486E-4 2.384E-2
1.935E-1
1.000E0
 3 199
31 M7948 Genes up-regulated in bone marrow-derived macrophages with STAT6 [GeneID=6778] knockout treated with rosiglitazone [PubChem=77999]: control versus IL4 [GeneID=3565]. MSigDB C7: Immunologic Signatures (v6.0) 5.486E-4 2.384E-2
1.935E-1
1.000E0
 3 199
32 M8356 Genes down-regulated in atherosclerosis macrophages: control anti miR ctrl versus untreated. MSigDB C7: Immunologic Signatures (v6.0) 5.486E-4 2.384E-2
1.935E-1
1.000E0
 3 199
33 M7270 Genes up-regulated in double positive thymocytes: TCF12 [GeneID=6939] knockout versus TCF3 and TCF12 [GeneID=6929;6938] knockout. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
34 M4108 Genes down-regulated in comparison of dendritic cells (DC) stimulated with Pam3Csk4 (TLR1/2 agonist) at 0.5 h versus those stimulated at 4 h. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
35 M5119 Genes up-regulated in comparison of CD4 [GeneID=920] dendritic cells (DC) versus CD8 DCs. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
36 M9640 Genes up-regulated in CD4 [GeneID=920] T helper cells (4h): Th0 versus TGFB1 and IL6 [GeneID=7040;3569]. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
37 M5623 Genes up-regulated in comparison of CD4 [GeneID=920] T cells treated with TGFB1 [GeneID=7040] versus those treated with TGFB3 [GeneID=7043] and IL6 [GeneID=3569]. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
38 M8958 Genes down-regulated in lymph node from aged mice: T reg versus T conv. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
39 M4075 Genes down-regulated in comparison of dendritic cells (DC) stimulated with LPS (TLR4 agonist) at 0.5 h versus those stimulated at 8 h. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
40 M4037 Genes up-regulated in comparison of dendritic cells (DC) stimulated with LPS (TLR4 agonist) at 0.5 h versus DC cells stimulated with Gardiquimod (TLR7 agonist) at 0.5 h. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
41 M7786 Genes down-regulated in NK cells: B3GAT1+ [GeneID=27087] versus B3GAT1- [GeneID=27087]. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
42 M8620 Genes down-regulated in bone marrow-derived dendritic cells: unstimulated versus CSF2 [GeneID=1437] and low dose of 1,3-beta-D-oligoglucan [PubChem=11375554]. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
43 M9770 Genes up-regulated in CD4 [GeneID=920] SMARTA effector T cells during acute infection of LCMV: follicular helper (Tfh) versus Ly6c int CXCR5+ [GeneID=643]. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
44 M9833 Genes up-regulated in at day 0 B cell IRF4-KO versus CD40L and IL-2 IL-4 IL-5 stimulated at day 1 B cell IRF4intermediate. MSigDB C7: Immunologic Signatures (v6.0) 5.567E-4 2.384E-2
1.935E-1
1.000E0
 3 200
45 18260157-Table3 Human Brain Ruano08 50genes GeneSigDB 5.921E-4 2.416E-2
1.962E-1
1.000E0
 2 44
46 15482854-Table2 Human Immune Sillanp04 48genes GeneSigDB 5.921E-4 2.416E-2
1.962E-1
1.000E0
 2 44
47 M19097 Genes up-regulated in the Kras2LA mouse lung cancer model with mutated KRAS [GeneID=3845]. MSigDB C2: CGP Curated Gene Sets (v6.0) 6.028E-4 2.416E-2
1.962E-1
1.000E0
 4 491
48 M2407 Genes regulated in MCF7 cells (breast cancer) by expression of full-length and truncated (611-CTF) forms of ERBB2 [GeneID=2064] at both 15 h and 60 h time points. MSigDB C2: CGP Curated Gene Sets (v6.0) 6.472E-4 2.540E-2
2.062E-1
1.000E0
 2 46
49 M16956 Genes up-regulated in hepatocellular carcinoma (HCC) cells with hepatic stem cell properties. MSigDB C2: CGP Curated Gene Sets (v6.0) 6.756E-4 2.598E-2
2.109E-1
1.000E0
 2 47
50 20564080-Table3 Human Leukemia Messina10 53genes GeneSigDB 7.046E-4 2.655E-2
2.156E-1
1.000E0
 2 48
Show 45 more annotations

14: Coexpression Atlas [Display Chart] 19 input genes in category / 521 annotations before applied cutoff / 21829 genes in category

No results to display

15: Computational [Display Chart] 16 input genes in category / 84 annotations before applied cutoff / 10037 genes in category

No results to display

16: MicroRNA [Display Chart] 19 input genes in category / 976 annotations before applied cutoff / 72241 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 TGCACTT,MIR-519B:MSigDB TGCACTT,MIR-519B:MSigDB MSigDB 7.136E-8 2.322E-5 1.732E-4 6.965E-5 5 421
2 TGCACTT,MIR-519A:MSigDB TGCACTT,MIR-519A:MSigDB MSigDB 7.136E-8 2.322E-5 1.732E-4 6.965E-5 5 421
3 TGCACTT,MIR-519C:MSigDB TGCACTT,MIR-519C:MSigDB MSigDB 7.136E-8 2.322E-5 1.732E-4 6.965E-5 5 421
4 hsa-miR-145-5p:Functional MTI Functional MTI miRTarbase 4.283E-7 7.693E-5 5.740E-4 4.180E-4 4 238
5 hsa-miR-10b-5p:TargetScan hsa-miR-10b-5p TargetScan 4.729E-7 7.693E-5 5.740E-4 4.616E-4 4 244
6 hsa-miR-10a-5p:TargetScan hsa-miR-10a-5p TargetScan 4.729E-7 7.693E-5 5.740E-4 4.616E-4 4 244
7 hsa-miR-892b:Functional MTI Functional MTI miRTarbase 8.715E-7 1.215E-4 9.067E-4 8.506E-4 3 71
8 hsa-miR-421:TargetScan hsa-miR-421 TargetScan 1.608E-6 1.872E-4 1.397E-3 1.569E-3 4 332
9 hsa-miR-5585-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.727E-6 1.872E-4 1.397E-3 1.685E-3 3 89
10 hsa-miR-768-3p:PITA hsa-miR-768-3p:PITA TOP PITA 2.192E-6 2.139E-4 1.596E-3 2.139E-3 4 359
11 hsa-miR-323-3p:PITA hsa-miR-323-3p:PITA TOP PITA 2.860E-6 2.538E-4 1.893E-3 2.791E-3 4 384
12 hsa-miR-193a-3p:Non-Functional MTI Non-Functional MTI miRTarbase 5.157E-6 4.194E-4 3.129E-3 5.033E-3 3 128
13 TCATCTC,MIR-143:MSigDB TCATCTC,MIR-143:MSigDB MSigDB 5.917E-6 4.442E-4 3.314E-3 5.775E-3 3 134
14 hsa-miR-579-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.007E-5 7.017E-4 5.236E-3 9.824E-3 3 160
15 hsa-miR-150:PITA hsa-miR-150:PITA TOP PITA 1.960E-5 1.276E-3 9.517E-3 1.913E-2 3 200
16 hsa-miR-143:PITA hsa-miR-143:PITA TOP PITA 2.604E-5 1.570E-3 1.172E-2 2.542E-2 3 220
17 TAGCTTT,MIR-9:MSigDB TAGCTTT,MIR-9:MSigDB MSigDB 2.784E-5 1.570E-3 1.172E-2 2.717E-2 3 225
18 hsa-miR-143-3p:Functional MTI Functional MTI miRTarbase 2.896E-5 1.570E-3 1.172E-2 2.827E-2 3 228
19 hsa-miR-153-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.719E-5 1.780E-3 1.328E-2 3.630E-2 3 248
20 hsa-miR-455-3p.2:TargetScan hsa-miR-455-3p.2 TargetScan 3.719E-5 1.780E-3 1.328E-2 3.630E-2 3 248
21 hsa-miR-513a-5p:PITA hsa-miR-513a-5p:PITA TOP PITA 4.279E-5 1.780E-3 1.328E-2 4.176E-2 3 260
22 hsa-miR-590-5p:PITA hsa-miR-590-5p:PITA TOP PITA 4.328E-5 1.780E-3 1.328E-2 4.224E-2 3 261
23 hsa-miR-21:PITA hsa-miR-21:PITA TOP PITA 4.427E-5 1.780E-3 1.328E-2 4.321E-2 3 263
24 hsa-miR-509-3p:Functional MTI Functional MTI miRTarbase 5.341E-5 1.780E-3 1.328E-2
5.213E-2
 2 41
25 hsa-miR-21-5p:TargetScan hsa-miR-21-5p TargetScan 5.502E-5 1.780E-3 1.328E-2
5.370E-2
 3 283
26 GTGCCAA,MIR-96:MSigDB GTGCCAA,MIR-96:MSigDB MSigDB 5.502E-5 1.780E-3 1.328E-2
5.370E-2
 3 283
27 hsa-miR-590-5p:TargetScan hsa-miR-590-5p TargetScan 5.560E-5 1.780E-3 1.328E-2
5.427E-2
 3 284
28 hsa-miR-199b-3p:PITA hsa-miR-199b-3p:PITA TOP PITA 6.412E-5 1.780E-3 1.328E-2
6.258E-2
 3 298
29 hsa-miR-199a-3p:PITA hsa-miR-199a-3p:PITA TOP PITA 6.412E-5 1.780E-3 1.328E-2
6.258E-2
 3 298
30 AGCACTT,MIR-520E:MSigDB AGCACTT,MIR-520E:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
31 AGCACTT,MIR-302D:MSigDB AGCACTT,MIR-302D:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
32 AGCACTT,MIR-302C:MSigDB AGCACTT,MIR-302C:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
33 AGCACTT,MIR-520B:MSigDB AGCACTT,MIR-520B:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
34 AGCACTT,MIR-93:MSigDB AGCACTT,MIR-93:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
35 AGCACTT,MIR-302B:MSigDB AGCACTT,MIR-302B:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
36 AGCACTT,MIR-302A:MSigDB AGCACTT,MIR-302A:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
37 AGCACTT,MIR-373:MSigDB AGCACTT,MIR-373:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
38 AGCACTT,MIR-520C:MSigDB AGCACTT,MIR-520C:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
39 AGCACTT,MIR-526B:MSigDB AGCACTT,MIR-526B:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
40 AGCACTT,MIR-520A:MSigDB AGCACTT,MIR-520A:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
41 AGCACTT,MIR-372:MSigDB AGCACTT,MIR-372:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
42 AGCACTT,MIR-520D:MSigDB AGCACTT,MIR-520D:MSigDB MSigDB 7.698E-5 1.780E-3 1.328E-2
7.514E-2
 3 317
43 hsa-miR-217:PITA hsa-miR-217:PITA TOP PITA 7.843E-5 1.780E-3 1.328E-2
7.655E-2
 3 319
44 hsa-miR-501-5p:PITA hsa-miR-501-5p:PITA TOP PITA 9.468E-5 2.100E-3 1.567E-2
9.241E-2
 3 340
45 hsa-miR-143-3p:TargetScan hsa-miR-143-3p TargetScan 9.885E-5 2.144E-3 1.600E-2
9.648E-2
 3 345
46 hsa-miR-1290:PITA hsa-miR-1290:PITA TOP PITA 1.058E-4 2.152E-3 1.606E-2
1.032E-1
 3 353
47 hsa-miR-199b-3p:TargetScan hsa-miR-199b-3p TargetScan 1.084E-4 2.152E-3 1.606E-2
1.058E-1
 3 356
48 hsa-miR-1271:PITA hsa-miR-1271:PITA TOP PITA 1.084E-4 2.152E-3 1.606E-2
1.058E-1
 3 356
49 hsa-miR-199a-3p:TargetScan hsa-miR-199a-3p TargetScan 1.084E-4 2.152E-3 1.606E-2
1.058E-1
 3 356
50 hsa-miR-96:PITA hsa-miR-96:PITA TOP PITA 1.103E-4 2.152E-3 1.606E-2
1.076E-1
 3 358
Show 45 more annotations

17: Drug [Display Chart] 19 input genes in category / 5970 annotations before applied cutoff / 22841 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 CID000025500 nickel hydroxide Stitch 2.494E-15 1.489E-11 1.381E-10 1.489E-11 10 259
2 CID000133005 CEP-1347 Stitch 6.044E-12 1.804E-8 1.673E-7 3.608E-8 6 59
3 ctd:C574276 GDC-0973 CTD 7.156E-11 1.424E-7 1.320E-6 4.272E-7 4 10
4 CID000005637 U0126 Stitch 9.493E-10 1.417E-6 1.314E-5 5.667E-6 8 431
5 CID000002199 AC1L1D59 Stitch 1.201E-9 1.433E-6 1.329E-5 7.167E-6 7 266
6 CID000443069 C11102 Stitch 7.503E-9 7.465E-6 6.922E-5 4.479E-5 5 86
7 CID000008515 SP600125 Stitch 1.014E-8 8.648E-6 8.018E-5 6.053E-5 7 362
8 CID000164810 kainite Stitch 1.761E-8 1.314E-5 1.218E-4 1.051E-4 4 35
9 CID000466138 AC1LAD18 Stitch 4.544E-8 3.014E-5 2.795E-4 2.713E-4 4 44
10 CID006918454 PD184352 Stitch 5.457E-8 3.258E-5 3.020E-4 3.258E-4 4 46
11 CID000004665 p38 MAP kinase inhibitor Stitch 6.265E-8 3.400E-5 3.153E-4 3.740E-4 5 131
12 CID000027933 inhibitor of p38 kinase Stitch 9.756E-8 4.854E-5 4.500E-4 5.824E-4 4 53
13 ctd:C560077 trametinib CTD 2.206E-7 9.812E-5 9.097E-4 1.317E-3 3 15
14 CID000446054 In-G Stitch 2.301E-7 9.812E-5 9.097E-4 1.374E-3 5 170
15 CID000000544 arsenite Stitch 2.704E-7 1.076E-4 9.977E-4 1.614E-3 6 347
16 CID000469261 AC1LAIW3 Stitch 3.393E-7 1.266E-4 1.174E-3 2.026E-3 4 72
17 ctd:C551177 vemurafenib CTD 3.791E-7 1.331E-4 1.234E-3 2.263E-3 4 74
18 ctd:C558666 TAK 733 CTD 6.556E-7 2.004E-4 1.858E-3 3.914E-3 2 2
19 ctd:C544830 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide CTD 6.556E-7 2.004E-4 1.858E-3 3.914E-3 2 2
20 CID000164073 Pkcs Stitch 6.714E-7 2.004E-4 1.858E-3 4.008E-3 5 211
21 CID006419759 K00077 Stitch 8.438E-7 2.399E-4 2.224E-3 5.037E-3 5 221
22 CID005311098 Ns102 Stitch 1.109E-6 3.011E-4 2.791E-3 6.623E-3 3 25
23 CID003005531 FTI-277 Stitch 1.610E-6 4.178E-4 3.874E-3 9.609E-3 4 106
24 CID000004122 nocodazole Stitch 1.752E-6 4.359E-4 4.042E-3 1.046E-2 6 478
25 ctd:C577924 RO5126766 CTD 1.966E-6 4.514E-4 4.185E-3 1.174E-2 2 3
26 ctd:C466792 GGTI 2147 CTD 1.966E-6 4.514E-4 4.185E-3 1.174E-2 2 3
27 ctd:D013431 Sulfates CTD 2.621E-6 5.795E-4 5.373E-3 1.565E-2 3 33
28 CID000007264 2a-c Stitch 3.724E-6 7.820E-4 7.250E-3 2.223E-2 3 37
29 ctd:C096898 L 744832 CTD 3.929E-6 7.820E-4 7.250E-3 2.346E-2 2 4
30 CID011526786 WAY-266176 Stitch 3.929E-6 7.820E-4 7.250E-3 2.346E-2 2 4
31 ctd:C471405 sorafenib CTD 6.246E-6 1.203E-3 1.115E-2 3.729E-2 4 149
32 ctd:C068836 N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime CTD 6.546E-6 1.221E-3 1.132E-2 3.908E-2 2 5
33 ctd:D006220 Haloperidol CTD 7.357E-6 1.331E-3 1.234E-2 4.392E-2 5 344
34 CID000216239 sorafenib Stitch 7.879E-6 1.383E-3 1.283E-2 4.704E-2 4 158
35 CID005289542 UV-C Stitch 8.911E-6 1.520E-3 1.409E-2
5.320E-2
 4 163
36 CID000122778 AC1L3V8L Stitch 9.814E-6 1.627E-3 1.509E-2
5.859E-2
 2 6
37 ctd:C012606 4-vinyl-1-cyclohexene dioxide CTD 1.052E-5 1.698E-3 1.574E-2
6.281E-2
 4 170
38 ctd:C440229 Oleylethanolamide CTD 1.373E-5 2.043E-3 1.894E-2
8.198E-2
 2 7
39 CID000004502 Nitr-5 Stitch 1.373E-5 2.043E-3 1.894E-2
8.198E-2
 2 7
40 ctd:D014873 Water Pollutants CTD 1.388E-5 2.043E-3 1.894E-2
8.285E-2
 3 57
41 1344 DN Adamantamine fumarate [80789-67-9]; Down 200; 9.6uM; HL60; HT HG-U133A Broad Institute CMAP Down 1.437E-5 2.043E-3 1.894E-2
8.580E-2
 4 184
42 CID000445722 AC1L9IGO Stitch 1.437E-5 2.043E-3 1.894E-2
8.580E-2
 4 184
43 CID000050980 pay off Stitch 1.540E-5 2.044E-3 1.895E-2
9.196E-2
 3 59
44 CID000003844 KT5720 Stitch 1.597E-5 2.044E-3 1.895E-2
9.535E-2
 4 189
45 2619 DN Thioguanosine [85-31-4]; Down 200; 12.6uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.631E-5 2.044E-3 1.895E-2
9.734E-2
 4 190
46 7439 DN Disopyramide [3737-09-5]; Down 200; 11.8uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.631E-5 2.044E-3 1.895E-2
9.734E-2
 4 190
47 425 UP staurosporine; Up 200; 0.01uM; MCF7; HG-U133A Broad Institute CMAP Up 1.734E-5 2.044E-3 1.895E-2
1.035E-1
 4 193
48 ctd:D006820 Hyaluronic Acid CTD 1.770E-5 2.044E-3 1.895E-2
1.057E-1
 4 194
49 2824 DN Isoquinoline, 6,7-dimethoxy-1-methyl-1,2,3,4-tetrahydro, hydrochloride; Down 200; 16.4uM; MCF7; HT HG-U133A Broad Institute CMAP Down 1.770E-5 2.044E-3 1.895E-2
1.057E-1
 4 194
50 5303 UP Methylergometrine maleate [113-42-8]; Up 200; 8.8uM; MCF7; HT HG-U133A Broad Institute CMAP Up 1.770E-5 2.044E-3 1.895E-2
1.057E-1
 4 194
Show 45 more annotations

18: Disease [Display Chart] 19 input genes in category / 1426 annotations before applied cutoff / 16205 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 OMIN:115150 CARDIOFACIOCUTANEOUS SYNDROME OMIM 1.349E-12 1.924E-9 1.509E-8 1.924E-9 4 4
2 C1837732 Thickened helices DisGeNET Curated 3.725E-12 2.656E-9 2.082E-8 5.312E-9 5 15
3 C0041409 Turner Syndrome, Male DisGeNET BeFree 1.885E-11 6.832E-9 5.356E-8 2.688E-8 6 51
4 C0018920 Hemangioma, Cavernous DisGeNET Curated 1.916E-11 6.832E-9 5.356E-8 2.733E-8 5 20
5 C0028326 Noonan Syndrome DisGeNET Curated 2.400E-11 6.844E-9 5.366E-8 3.422E-8 6 53
6 C3551431 Sparse or absent eyelashes DisGeNET Curated 4.713E-11 8.400E-9 6.586E-8 6.720E-8 4 7
7 C1835157 Partial to total absence of eyelashes DisGeNET Curated 4.713E-11 8.400E-9 6.586E-8 6.720E-8 4 7
8 C1862855 Sparse to absent eyelashes DisGeNET Curated 4.713E-11 8.400E-9 6.586E-8 6.720E-8 4 7
9 C1857539 Deep palmar crease DisGeNET Curated 9.418E-11 1.492E-8 1.170E-7 1.343E-7 4 8
10 C4280532 Decreased width of the skull DisGeNET Curated 1.208E-10 1.566E-8 1.228E-7 1.722E-7 5 28
11 C1854418 Biparietal narrowing DisGeNET Curated 1.208E-10 1.566E-8 1.228E-7 1.722E-7 5 28
12 C1328931 Multiple lentigines DisGeNET Curated 2.821E-10 3.095E-8 2.426E-7 4.023E-7 4 10
13 C4025662 Abnormality of the ulna DisGeNET Curated 2.821E-10 3.095E-8 2.426E-7 4.023E-7 4 10
14 C0221217 Neck webbing DisGeNET Curated 3.969E-10 4.043E-8 3.170E-7 5.660E-7 5 35
15 C4025846 Abnormality of vision DisGeNET Curated 9.123E-10 8.542E-8 6.697E-7 1.301E-6 5 41
16 C1275081 Cardio-facio-cutaneous syndrome DisGeNET Curated 9.584E-10 8.542E-8 6.697E-7 1.367E-6 4 13
17 C0558165 Curly hair (finding) DisGeNET Curated 1.341E-9 1.125E-7 8.818E-7 1.912E-6 4 14
18 C4024890 Excessive wrinkled skin DisGeNET Curated 2.434E-9 1.589E-7 1.246E-6 3.471E-6 4 16
19 C2748653 Chubby cheeks DisGeNET Curated 2.563E-9 1.589E-7 1.246E-6 3.654E-6 5 50
20 C4280648 Hyperplasia of cheeks DisGeNET Curated 2.563E-9 1.589E-7 1.246E-6 3.654E-6 5 50
21 C3806443 Puffy cheeks DisGeNET Curated 2.563E-9 1.589E-7 1.246E-6 3.654E-6 5 50
22 C4280647 Hypertrophy of cheeks DisGeNET Curated 2.563E-9 1.589E-7 1.246E-6 3.654E-6 5 50
23 C1866231 Full cheeks DisGeNET Curated 2.563E-9 1.589E-7 1.246E-6 3.654E-6 5 50
24 C1956257 Pulmonary Stenosis DisGeNET Curated 2.839E-9 1.687E-7 1.323E-6 4.049E-6 5 51
25 C1855728 Low posterior hairline DisGeNET Curated 3.139E-9 1.745E-7 1.368E-6 4.476E-6 5 52
26 C1849340 Long palpebral fissure DisGeNET Curated 3.181E-9 1.745E-7 1.368E-6 4.536E-6 4 17
27 C1861975 Cafe au lait spots, multiple DisGeNET Curated 4.087E-9 2.081E-7 1.632E-6 5.828E-6 4 18
28 C3551426 Dystrophic fingernails DisGeNET Curated 4.087E-9 2.081E-7 1.632E-6 5.828E-6 4 18
29 C1832348 Slow-growing hair DisGeNET Curated 5.173E-9 2.544E-7 1.994E-6 7.376E-6 4 19
30 C0406484 Sebaceous hyperplasia DisGeNET BeFree 5.462E-9 2.596E-7 2.036E-6 7.789E-6 3 4
31 C4280369 Flattening of the zygomatic bone DisGeNET Curated 9.740E-9 3.754E-7 2.943E-6 1.389E-5 4 22
32 C0036651 Senile lentigo DisGeNET Curated 9.740E-9 3.754E-7 2.943E-6 1.389E-5 4 22
33 C4024878 Generalized hyperpigmentation DisGeNET Curated 9.740E-9 3.754E-7 2.943E-6 1.389E-5 4 22
34 C4280368 Hypotrophic cheekbone DisGeNET Curated 9.740E-9 3.754E-7 2.943E-6 1.389E-5 4 22
35 C4280370 Depressed cheekbone DisGeNET Curated 9.740E-9 3.754E-7 2.943E-6 1.389E-5 4 22
36 C4021242 Hypoplasia of the zygomatic bone DisGeNET Curated 9.740E-9 3.754E-7 2.943E-6 1.389E-5 4 22
37 C4072879 Small cheekbone DisGeNET Curated 9.740E-9 3.754E-7 2.943E-6 1.389E-5 4 22
38 C0206620 Lymphangioma, Cystic DisGeNET Curated 1.178E-8 4.421E-7 3.467E-6 1.680E-5 4 23
39 C0020757 Ichthyoses DisGeNET Curated 1.341E-8 4.903E-7 3.844E-6 1.912E-5 5 69
40 C1970705 Fragile hair DisGeNET Curated 1.681E-8 5.706E-7 4.474E-6 2.397E-5 4 25
41 C4072837 Fractured hair DisGeNET Curated 1.681E-8 5.706E-7 4.474E-6 2.397E-5 4 25
42 C1851868 Reduced tensile strength of hair DisGeNET Curated 1.681E-8 5.706E-7 4.474E-6 2.397E-5 4 25
43 C0423110 Downward slant of palpebral fissure DisGeNET Curated 1.982E-8 6.572E-7 5.153E-6 2.826E-5 6 159
44 C0263490 Brittle hair DisGeNET Curated 2.328E-8 7.546E-7 5.916E-6 3.320E-5 4 27
45 C0587248 Costello syndrome (disorder) DisGeNET Curated 2.714E-8 8.601E-7 6.744E-6 3.871E-5 4 28
46 C2266639 Absence of eyebrows DisGeNET Curated 4.753E-8 1.356E-6 1.063E-5 6.778E-5 4 32
47 C1848765 Sparse/absent eyebrows DisGeNET Curated 4.753E-8 1.356E-6 1.063E-5 6.778E-5 4 32
48 C0241074 Skin hyperelastic DisGeNET Curated 4.753E-8 1.356E-6 1.063E-5 6.778E-5 4 32
49 C4021956 Aplasia/Hypoplasia of the eyebrow DisGeNET Curated 4.753E-8 1.356E-6 1.063E-5 6.778E-5 4 32
50 C3551430 Sparse or absent eyebrows DisGeNET Curated 4.753E-8 1.356E-6 1.063E-5 6.778E-5 4 32
Show 45 more annotations